Community-acquired Pneumonia, Pneumococcal Infections, Pneumonia
Conditions
Keywords
France, Vaccine, pneumococcal infections
Brief summary
CAP'Hospi is an observational, multicentric study in France which primary objective is to describe the proportion of Community Acquired Pneumonia due to serotypes included in PCV20 among adults hospitalized for CAP
Interventions
None listed
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults 18 years of age or older 2. Admission to hospital for at least 24 hours 3. Suspicion of community-acquired pneumonia at admission defined as the association of: Radiologic findings consistent with pneumonia (eg, pleural effusion, increased pulmonary density due to infection and/or alveolar infiltrates \[multilobar, lobar, or segmental\] containing air bronchograms), AND The presence of ≥2 of the following signs or symptoms: Fever (oral temperature \>38°C or tympanic temperature \>38.5°C) in the 24 hours preceding admission; Hypothermia (\<35.5°C measured by a healthcare provider) in the 24 hours preceding admission ; Chills or rigors ; Pleuritic chest pain ; New or worsening cough ; Sputum production ; Dyspnea (shortness of breath); Tachypnea (respiratory rate \>20/min) ; Malaise ; Abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation) 4. Written informed consent from the patient
Exclusion criteria
1. Suspicion of tuberculosis 2. Individuals placed under judicial protection 3. Individuals who refuse the transfer of biological samples to the USA 4. Patient developing signs and symptoms of pneumonia after having been hospitalized for 48 hours or more 5. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| proportions of S. pneumoniae serotypes included in PCV20 | 2 years | The proportion will be determined by UAD assay and/or culture from any sites overall and by age and risk group among adults hospitalized with CAP |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patients hospital trajectories | 2 years | The proportion of patients who died from any cause, the proportion of patients requiring mechanical ventilation within the first 30 days of hospitalization, the proportion of patients who required transfer to ICU within the first 30 days of hospitalization, the length of ICU-stay, the length of hospital-stay, the proportion of patients who required hospital re-admission |
| Patients hospital stay by serotype groups | 2 years | The proportion of patients who died from any cause, the proportion of patients requiring mechanical ventilation within the first 30 days of hospitalization, the proportion of patients who required transfer to ICU within the first 30 days of hospitalization, the length of ICU-stay, the length of hospital-stay, the proportion of patients who required hospital re-admission |
| proportion of serotypes of S. pneumoniae by group | 2 years | Among adults hospitalized for all-cause CAP or pneumococcal CAP the proportion of serotypes of S. pneumoniae grouped by serotypes included into pneumococcal vaccines and individual serotypes, by age and risk group |
| The proportion of patients with a severe CAP | 2 years | transfer to the ICU during hospitalization. Studied factors will include baseline characteristics of patients and pneumococcal and pneumococcal serotype pneumonia etiology |
| The proportion of patients who required re-hospitalization following hospital discharge | 2 years | Studied factors will include baseline characteristics of patients and pneumococcal and pneumococcal serotype pneumonia etiology |
| Prevalence of different bacterial and viral causes of hospitalized CAP | 2 years | description of the proportion of bacteria and virus attributable to each patients |
Countries
France
Outcome results
None listed